Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

Invest New Drugs

Department of Gynaecology and Obstetrics, National Center for Tumour Diseases, University of Heidelberg, 69115 Heidelberg, Germany.

Published: August 2012

Download full-text PDF	Source
http://dx.doi.org/10.1007/s10637-011-9688-3	DOI Listing

Publication Analysis

cytotoxicity antimetabolite-bisphosphonate

antimetabolite-bisphosphonate 5-fdu-alendronate

5-fdu-alendronate comparison

comparison standard

standard therapeutics

therapeutics breast

breast ovarian

ovarian cancer

cancer cell

cell lines

Invest New Drugs

August 2012

Department of Gynaecology and Obstetrics, National Center for Tumour Diseases, University of Heidelberg, 69115 Heidelberg, Germany.

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!